Cherry J D, Heininger U, Stehr K, Christenson P
Department of Pediatrics and the University of California, Los Angeles Center for Vaccine Research, University of California, Los Angeles School of Medicine, Los Angeles, California, USA.
Pediatrics. 1998 Oct;102(4 Pt 1):909-12. doi: 10.1542/peds.102.4.909.
In the course of a large pertussis vaccine efficacy trial we realized that investigator compliance could have a major impact on calculated vaccine efficacy.
In our pertussis vaccine efficacy trial, the study investigators were to monitor illness in study families by telephone every 2 weeks. If a cough illness of >/=7 days duration was noted, the study child was to be evaluated. If the cough illness persisted for >/=14 days, the child was to be referred to a central investigator. For this report we analyzed study physician evaluation rates and rates of referral to the central investigators. Physician practices were separated into three compliance categories: high, intermediate, and low. We analyzed vaccine efficacy of an acellular pertussis component DTP vaccine (DTaP) and a whole cell pertussis component DTP vaccine (DTP) by compliance category. Bordetella pertussis infection was documented by culture of the organism in the study child or in a household contact or by a significant antibody response to pertussis toxin determined by enzyme-linked immunosorbent assay.
Using a clinical case definition that included both mild and typical pertussis (cough illness >/=7 days duration) efficacy of DTaP vaccine was 40% (95% confidence interval [CI] = -3-65) in the high compliance category and 78% (95% CI = 65-86) and 75% (95% CI = 53-87) in the intermediate and low compliance groups, respectively. Similar, but less marked, differences in efficacy were noted with DTP vaccine recipients. Using a clinical case definition that required >/=21 days of cough with paroxysms, whoop, or vomiting (typical pertussis) the efficacy of DTaP vaccine was 69% (95% CI = 41-83) in the high compliance category and 86% (95% CI = 76-92) and 84% (95% CI = 64-93) in the intermediate and low compliance groups, respectively. In contrast, the efficacy of DTP vaccine did not vary by compliance category using this case definition. The attack rate in children vaccinated with diphtheria and tetanus toxoids vaccine (DT) was twofold less in low compliance physician practices when compared with the rates in high and intermediate groups. The DT/DTaP and DT/DTP fold-change differences were less in the high compliance group compared with the intermediate and low compliance groups.
Our data suggest that observer compliance (observer bias), can significantly inflate calculated vaccine efficacy. It is likely that all recently completed efficacy trials have been effected by this type of observer bias and all vaccines have considerably less efficacy against mild disease than published data suggest.
在一项大型百日咳疫苗效力试验过程中,我们意识到研究者的依从性可能对计算出的疫苗效力产生重大影响。
在我们的百日咳疫苗效力试验中,研究人员需每两周通过电话监测研究家庭中的疾病情况。若发现咳嗽持续时间≥7天的疾病,需对患病儿童进行评估。若咳嗽疾病持续≥14天,则该儿童需转诊至中心研究人员处。在本报告中,我们分析了研究医生的评估率以及转诊至中心研究人员的比率。医生的做法被分为三个依从性类别:高、中、低。我们按依从性类别分析了无细胞百日咳组分白百破疫苗(DTaP)和全细胞百日咳组分白百破疫苗(DTP)的疫苗效力。通过在患病儿童或家庭接触者中培养该病原体或通过酶联免疫吸附测定法测定的对百日咳毒素的显著抗体反应来记录百日咳博德特氏菌感染情况。
采用包括轻度和典型百日咳(咳嗽持续时间≥7天)的临床病例定义,在高依从性类别中,DTaP疫苗的效力为40%(95%置信区间[CI]=-3 - 65),在中等和低依从性组中分别为78%(95%CI = 65 - 86)和75%(95%CI = 53 - 87)。在DTP疫苗接种者中也观察到了类似但不太明显的效力差异。采用要求咳嗽伴阵发性痉挛、鸡鸣样吸气吼声或呕吐≥21天(典型百日咳)的临床病例定义,在高依从性类别中,DTaP疫苗的效力为69%(95%CI = 41 - 83),在中等和低依从性组中分别为86%(95%CI = 76 - 92)和84%(95%CI = 64 - 93)。相比之下,使用此病例定义时,DTP疫苗的效力在不同依从性类别中无差异。与高和中等依从性组相比,在低依从性医生诊疗中接种白喉和破伤风类毒素疫苗(DT)的儿童的发病率降低了一半。与中等和低依从性组相比,高依从性组中DT/DTaP和DT/DTP的倍数变化差异较小。
我们的数据表明,观察者的依从性(观察者偏差)可显著夸大计算出的疫苗效力。近期所有完成的效力试验可能都受到了这种观察者偏差的影响,并且所有疫苗对轻症疾病的效力都远低于已发表数据所显示的水平。